AAAAAA

   
Results: 1-15 |
Results: 15
IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: ZEDER K WALLER EK REDEI I CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD HOLDEN J HOLLAND K JONES W MCCOLLUM J MOGUL M PHILLIPS C RODEY G WINGARD JR WINTON E YEAGER AM DEVINE S
Citation: K. Zeder et al., IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cancer research, therapy & control, 5(4), 1998, pp. 221-228
PRESENCE OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS PREALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IS ASSOCIATED WITH A LOWER RELAPSE-FREE SURVIVAL (RFS)
Authors: HOLLAND HK BRAY RA OTOOLE K HOLDEN JT CONNAGHAN DG HEFFNER LT WALLER EK WINTON EF YEAGER AM
Citation: Hk. Holland et al., PRESENCE OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS PREALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT) IS ASSOCIATED WITH A LOWER RELAPSE-FREE SURVIVAL (RFS), Experimental hematology, 25(8), 1997, pp. 621-621
SERIAL MEASUREMENT OF SERUM HYALURONIC-ACID IN VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) - CORRELATION WITH SEVERITY
Authors: FRIED MW DUNCAN A SOROKA S CONNAGHAN DG FARRAND A STRAUSS RM BOYER TD MCDONALD GB
Citation: Mw. Fried et al., SERIAL MEASUREMENT OF SERUM HYALURONIC-ACID IN VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT) - CORRELATION WITH SEVERITY, Hepatology, 26(4), 1997, pp. 82-82
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (PEG-RHUMGDF)IN BREAST-CANCER PATIENTS (PTS) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT)
Authors: BEVERIDGE R SCHUSTER M WALLER E STUART R ABBOUD C CRUICKSHANK S MENCHACA D MACRI M CONNAGHAN DG
Citation: R. Beveridge et al., RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR (PEG-RHUMGDF)IN BREAST-CANCER PATIENTS (PTS) FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT), Blood, 90(10), 1997, pp. 2580-2580
MINIMAL TOXICITY AND MORTALITY IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN PLUS AUTOLOGOUS MARROW STEM-CELL TRANSPLANTATION AND COMPREHENSIVE SUPPORTIVE CARE
Authors: HOLLAND HK DIX SP GELLER RB DEVINE SM HEFFNER LT CONNAGHAN DG HILLYER CD HUGHES LL MILLER RL MOORE MR WINTON EF WINGARD JR
Citation: Hk. Holland et al., MINIMAL TOXICITY AND MORTALITY IN HIGH-RISK BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN PLUS AUTOLOGOUS MARROW STEM-CELL TRANSPLANTATION AND COMPREHENSIVE SUPPORTIVE CARE, Journal of clinical oncology, 14(4), 1996, pp. 1156-1164
SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL)
Authors: HOLLAND HK FLEMING WH WALLER EK GELLER RB CONNAGHAN DG DEVINE SD YEAGER AM
Citation: Hk. Holland et al., SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL), Experimental hematology, 24(9), 1996, pp. 631-631
SERUM HYALURONIC-ACID AS A MARKER OF LIVER-INJURY IN VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT)
Authors: FRIED MW DUNCAN A SOROKA S CONNAGHAN DG RUOCCO C STRAUSS RM BOYER TD
Citation: Mw. Fried et al., SERUM HYALURONIC-ACID AS A MARKER OF LIVER-INJURY IN VENOOCCLUSIVE DISEASE (VOD) FOLLOWING BONE-MARROW TRANSPLANTATION (BMT), Hepatology, 24(4), 1996, pp. 1355-1355
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT FOR THE MANAGEMENT OF SEVERE VENOOCCLUSIVE DISEASE FOLLOWING BONE-MARROW TRANSPLANTATION
Authors: FRIED MW CONNAGHAN DG SHARMA S MARTIN LG DEVINE S HOLLAND K ZUCKERMAN A KAUFMAN S WINGARD J BOYER TD
Citation: Mw. Fried et al., TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT FOR THE MANAGEMENT OF SEVERE VENOOCCLUSIVE DISEASE FOLLOWING BONE-MARROW TRANSPLANTATION, Hepatology, 24(3), 1996, pp. 588-591
SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL)
Authors: HOLLAND HK FLEMING WH WALLER EK CONNAGHAN DG GELLER RB WINGARD JR YEAGER AM
Citation: Hk. Holland et al., SELECTION AND TRANSPLANTATION OF AUTOLOGOUS CD34-BLOOD STEM-CELLS IN NON-HODGKINS-LYMPHOMA USING HIGH-SPEED FLUORESCENCE-ACTIVATED CELL SORTING( PERIPHERAL), Blood, 88(10), 1996, pp. 1616-1616
TRANSJUGULAR INTRAHEPATIC PORTAL-SYSTEMIC SHUNT (TIPS) FOR THE MANAGEMENT OF SEVERE VENOOCCLUSIVE DISEASE (VOD) AFTER BONE-MARROW TRANSPLANTATION (BMT)
Authors: FRIED MW CONNAGHAN DG SHARMA S MARTIN L DEVINE S HOLLAND K ZUCKERMAN A KAUFMAN S WINGARD J BOYER TD
Citation: Mw. Fried et al., TRANSJUGULAR INTRAHEPATIC PORTAL-SYSTEMIC SHUNT (TIPS) FOR THE MANAGEMENT OF SEVERE VENOOCCLUSIVE DISEASE (VOD) AFTER BONE-MARROW TRANSPLANTATION (BMT), Hepatology, 22(4), 1995, pp. 591-591
TOTAL CD34-GEMM ARE NOT GOOD PREDICTORS OF TIME TO NEUTROPHIL ENGRAFTMENT FOLLOWING MATCHED UNRELATED DONOR (MUD) TRANSPLANTATION( CELL CONTENT AND CFU)
Authors: HOLLAND HK GELLER RB REDEI S BRAY R WINTON EF CONNAGHAN DG OTOOLE K PERSON L DEVINE SM WINGARD JR
Citation: Hk. Holland et al., TOTAL CD34-GEMM ARE NOT GOOD PREDICTORS OF TIME TO NEUTROPHIL ENGRAFTMENT FOLLOWING MATCHED UNRELATED DONOR (MUD) TRANSPLANTATION( CELL CONTENT AND CFU), Blood, 86(10), 1995, pp. 467-467
PHASE-I TRIAL OF BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY), AND DIAZIQUONE(AZQ) FOLLOWING AUTOLOGOUS (AU) OR ALLOGENEIC (AL) BONE-MARROW TRANSPLANTATION (BMT)
Authors: DEVINE SM DIX SP GELLER RB HOLLAND HK COLBAUGH J CONNAGHAN DG FLEMING WH HILLYER CD MULLINS R WALLER EK WINTON EF WINGARD JR
Citation: Sm. Devine et al., PHASE-I TRIAL OF BUSULFAN (BU), CYCLOPHOSPHAMIDE (CY), AND DIAZIQUONE(AZQ) FOLLOWING AUTOLOGOUS (AU) OR ALLOGENEIC (AL) BONE-MARROW TRANSPLANTATION (BMT), Blood, 86(10), 1995, pp. 831-831
EVALUATION OF SUPPORTIVE CARE GUIDELINES FOR MONITORING BREAST-CANCERBONE-MARROW TRANSPLANT (BMT) PATIENTS IN THE OUTPATIENT SETTING
Authors: MIYAHARA TT DIX SP DEVINE SM HOLLAND HK CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD WALLER EK WINTON EF WINGARD JR
Citation: Tt. Miyahara et al., EVALUATION OF SUPPORTIVE CARE GUIDELINES FOR MONITORING BREAST-CANCERBONE-MARROW TRANSPLANT (BMT) PATIENTS IN THE OUTPATIENT SETTING, Blood, 86(10), 1995, pp. 838-838
TRANSPLANTATION OF HLA-IDENTICAL POSITIVELY SELECTED CD34-BLOOD (PBSC) AND MARROW (BM) FROM RELATED DONORS RESULTS IN PROMPT ENGRAFTMENT AND LOW INCIDENCE OF GVHD IN RECIPIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION( CELLS OF PERIPHERAL)
Authors: HOLLAND HK BRAY AM GELLER RB DEVINE SM MCCOLLUM J CONNAGHAN DG FLEMING WH HEFFNER LT HILLYER C WALLER EK WINTON EF WINGARD JR
Citation: Hk. Holland et al., TRANSPLANTATION OF HLA-IDENTICAL POSITIVELY SELECTED CD34-BLOOD (PBSC) AND MARROW (BM) FROM RELATED DONORS RESULTS IN PROMPT ENGRAFTMENT AND LOW INCIDENCE OF GVHD IN RECIPIENTS UNDERGOING ALLOGENEIC TRANSPLANTATION( CELLS OF PERIPHERAL), Blood, 86(10), 1995, pp. 1543-1543
TACROLIMUS (FK506) COMBINED WITH METHOTREXATE (MTX) IS EFFECTIVE IN PREVENTING ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) FOLLOWING RELATED DONOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
Authors: DEVINE SM GELLER RB DIX SP CONNAGHAN DG FLEMING WH HEFFNER LT HILLYER CD HOLLAND HK WALLER EK WINTON EF WINGARD JR
Citation: Sm. Devine et al., TACROLIMUS (FK506) COMBINED WITH METHOTREXATE (MTX) IS EFFECTIVE IN PREVENTING ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) FOLLOWING RELATED DONOR ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 86(10), 1995, pp. 1569-1569
Risultati: 1-15 |